Access to multi-indication medicines in underserved autoimmune diseases: Are there better approaches to supporting sustainable access? — Dolon

— Whittal A, Epstein J, Lazareva Y, Cole A, Jommi C, Barros PP, Wollaert L, Patris J.

Value & Outcomes Spotlight. 2025.

Click here to explore our ongoing work on multi-indication medicines

Related articles

Supporting patients with underserved autoimmune diseases: Challenges and opportunities for innovative medicines
Multi-indication Medicines14/09/2025

Pricing and reimbursement of multiple indication medicines: Can a balance be found between different stakeholder perspectives to optimise value and access for patients, while ensuring sustainable and affordable innovation?
Multi-indication Medicines17/11/2024